中国西部地区2型糖尿病患者自我管理知识、态度和行为的干预性评估

注册号:

Registration number:

ChiCTR2400079653 

最近更新日期:

Date of Last Refreshed on:

2024-01-09 08:19:44 

注册时间:

Date of Registration:

2024-01-09 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

中国西部地区2型糖尿病患者自我管理知识、态度和行为的干预性评估

Public title:

Assessment of self management knowledge, attitudes and behaviors of type 2 diabetes mellitus patients in western China

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中国西部地区2型糖尿病患者自我管理知识、态度和行为的干预性评估

Scientific title:

Assessment of self management knowledge, attitudes and behaviors of type 2 diabetes mellitus patients in western China

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘茜 

研究负责人:

冯变玲 

Applicant:

Liu Qian 

Study leader:

Feng Bianling 

申请注册联系人电话:

Applicant telephone:

+86 187 3434 0511

研究负责人电话:

Study leader's
telephone:

+86 153 0926 9476

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liuqian10231@163.com

研究负责人电子邮件:

Study leader's E-mail:

fengbianling@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

陕西省西安市雁塔区雁塔西路76号

研究负责人通讯地址:

陕西省西安市雁塔区雁塔西路76号

Applicant address:

76 Yanta Road West, Yanta District, Xi'an, Shaanxi

Study leader's address:

76 Yanta Road West, Yanta District, Xi'an, Shaanxi

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

西安交通大学医学部

Applicant's institution:

Medical Department, Xi'an Jiaotong University

研究负责人所在单位:

西安交通大学医学部

Affiliation of the Leader:

Medical Department, Xi'an Jiaotong University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022-1763

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

西安交通大学医学部生物医学伦理委员会

Name of the ethic committee:

Ethics Committee of Biomedicine, Department of Medicine, Xi'an Jiaotong University

伦理委员会批准日期:

Date of approved by ethic committee:

2022-12-01 00:00:00

伦理委员会联系人:

陈腾

Contact Name of the ethic committee:

Chen Teng

伦理委员会联系地址:

陕西省西安市雁塔区雁塔西路76号

Contact Address of the ethic committee:

76 Yanta Road West, Yanta District, Xi'an, Shaanxi

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 29 8265 7977

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

西安交通大学医学部

Primary sponsor:

Medical Department, Xi'an Jiaotong University

研究实施负责(组长)单位地址:

陕西省西安市雁塔区雁塔西路76号

Primary sponsor's address:

76 Yanta Road West, Yanta District, Xi'an, Shaanxi

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西

市(区县):

西安

Country:

China

Province:

Shaanxi

City:

Xi'an

单位(医院):

西安交通大学

具体地址:

雁塔区雁塔西路76号

Institution
hospital:

Xi'an Jiaotong University

Address:

76 Yanta Road West, Yanta District

经费或物资来源:

该工作获得陕西省科学技术厅科技计划项目科研费 (2021SF-177)资助。

Source(s) of funding:

This work was funded by the scientific research fund (2021SF-177) of the Science and Technology Plan Project of the Department of Science and Technology of Shaanxi Province.

研究疾病:

2型糖尿病  

Target disease:

Type 2 diabetes mellitus

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究旨在评估社区家庭医生的干预对于提高2型糖尿病患者的自我管理能力和药物依从性的影响效果及作用,从而为促进糖尿病患者自我管理能力的提升以及完善基层社区糖尿病防治管理的工作提供参考依据。  

Objectives of Study:

The study aims to assess the impact and effectiveness of interventions by community family physicians in improving self-management abilities and medication adherence among patients with type 2 diabetes. The findings will serve as a reference for enhancing the self-management capabilities of diabetes patients and improving the management of diabetes prevention and control at the grassroots community level.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

(1)糖尿病合并有严重的并发症,如严重糖尿病肾病、糖尿病性视网膜严重病变等;(2)伴随其他严重的身体疾病;(3)有精神异常和认知障碍的患者;(4)同时患有肿瘤并且半年内接受过化疗、放疗等治疗的患者;(5)患有特殊类型糖尿病或其他不适合本研究的疾病;(6)正在参加其他研究课题的患者。

Exclusion criteria:

(1) Diabetes with serious complications, such as severe diabetic nephropathy, severe diabetic retinopathy, etc.; (2) with other serious physical diseases; (3) patients with mental disorders and cognitive impairments; (4) patients concurrently diagnosed with cancer and having received chemotherapy, radiotherapy or other treatments within the past six months; (5) suffering from special types of diabetes or other diseases not suitable for this study; (6) patients who are participating in other research projects.

研究实施时间:

Study execute time:

From 2022-12-01 00:00:00 To 2023-08-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-02-26 00:00:00 To 2023-06-30 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

90

Group:

Intervention group

Sample size:

干预措施:

社区的常规糖尿病管理+知识教育与服药提醒服务+个性化随访与指导评估服务

干预措施代码:

Intervention:

Routine diabetes management in the community+Integrated knowledge education and medication reminder service+Personalized follow-up and guidance assessment service

Intervention code:

组别:

对照组

样本量:

90

Group:

control group

Sample size:

干预措施:

社区的常规糖尿病管理

干预措施代码:

Intervention:

Routine diabetes management in the community

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China

Province:

Shaanxi

City:

Xi'an

单位(医院):

西安市灞桥区社区健康中心 

单位级别:

社区卫生服务中心 

Institution
hospital:

Baqiao District Community Health Center

Level of the institution:

Community Health Service Center

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China

Province:

Shaanxi

City:

Xi'an

单位(医院):

西安市雁塔区社区卫生服务中心 

单位级别:

社区卫生服务中心 

Institution
hospital:

Yanta District Community Health Center

Level of the institution:

Community Health Service Center

测量指标:

Outcomes:

指标中文名:

糖化血红蛋白

指标类型:

主要指标

Outcome:

Glycosylated haemoglobin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

知识、态度和行为评分

指标类型:

次要指标

Outcome:

Knowledge, attitude, behavior scores

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

药物依从性评分

指标类型:

次要指标

Outcome:

Medication adherence

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 31 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

试验所选取的两个区的所有社区医院都被编号。使用计算机生成的随机数,随机选择社区医院。使用西安市社区健康档案管理系统,导出所选社区医院老年人的健康信息,从1到n排序。通过随机数软件生成180个号码的相应老年人作为样本。

Randomization Procedure (please state who generates the random number sequence and by what method):

All community hospitals in the two districts selected for the trial were numbered. Then use computer-generated random numbers to randomly select community hospitals. Use the Xi'an community health file management system to export the health information of the elderly in the selected community hospital, sorted from 1 to n. Generate corresponding random numbers for 180 individuals using random number software to serve as the sample.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

在完成该研究和发表文章之后,数据将在本网站ResMan上传。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After completion of the trial and the paper publication, the data can be shared on the web of ResMan.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本实验采用问卷形式搜集数据,在数据搜集完毕后,由我们的数据分析负责人对研究对象的相关数据进行分析。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

After the study, data will be entered on a double-entry basis by research assistants to ensure the quality of data and then the statistician will receive the data of study objects at the end of the trial.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-01-09 08:16:34